NASDAQ$WVE
Wave Life Sciences Ltd · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Wave Life Sciences reported financial results for Q4 2019 and provided a business update.
Wave Life Sciences reported a net loss of $56.8 million in the fourth quarter of 2019, compared to a net loss of $37.9 million in the same period in 2018. The increase in net loss was primarily driven by increased research and development efforts and continued organizational growth.
- Advanced CNS-focused pipeline of stereopure oligonucleotides.
- Initiated dosing in a 32 milligram (mg) dose cohort in the PRECISION-HD2 Phase 1b/2a clinical trial of WVE-120102 in January 2020.
- Expect to initiate clinical development for SNP3 and C9orf72 programs in 2H 2020.
- Presented proof-of-concept data for RNA-editing program in January, expecting initial in vivo results in 2020.
Headline financials
Revenue & EPS history
Wave Life Sciences · Revenue · Quarterly
$2.4M
Forward guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from existing collaborations, will enable Wave to fund its operating and capital expenditure requirements into the third quarter of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
+1.9%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+8.2%
Avg return
30 days after
48%
20 / 42 earnings
Positive
+42.4%
Q4 2023
Best reaction
-16.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +8.4% | +5.3% | -6.9% | |
| Q4 2025 | +5.6% | -7.6% | -56.2% | |
| Q3 2025 | -10.3% | -9.9% | +157.4% | |
| Q1 2025 | +0.5% | -1.5% | +11.2% | |
| Q4 2024 | +11.7% | -6.5% | -33.9% | |
| Q3 2024 | -4.6% | -16.8% | -15.8% | |
| Q2 2024 | -9.5% | -6.9% | -14.2% | |
| Q1 2024 | -3.9% | -0.2% | -0.7% | |
| Q4 2023 | +42.4% | +42.0% | +23.4% | |
| Q3 2023 | -8.9% | -5.6% | -21.7% | |
| Q2 2023 | +14.4% | +3.0% | +3.9% | |
| Q1 2023 | -0.8% | +8.2% | +23.6% | |
| Q4 2022 | -11.1% | -11.8% | +1.9% | |
| Q3 2022 | -7.6% | -19.3% | -1.3% | |
| Q2 2022 | +37.3% | +45.1% | +26.7% | |
| Q1 2022 | -16.3% | -13.6% | +46.3% | |
| Q4 2021 | -5.7% | -17.1% | -17.5% | |
| Q3 2021 | +1.5% | -3.2% | -25.7% | |
| Q2 2021 | +7.0% | -0.4% | +12.3% | |
| Q1 2021 | +1.5% | +9.6% | +18.3% | |
| Q4 2020 | -7.8% | -8.9% | -40.5% | |
| Q3 2020 | +2.8% | +11.9% | +19.3% | |
| Q2 2020 | +1.5% | -0.5% | +36.9% | |
| Q1 2020 | +28.2% | +30.2% | +28.1% | |
| Q4 2019 | -3.2% | +9.8% | +6.6% | |
| Q3 2019 | -1.0% | +3.1% | +20.9% | |
| Q2 2019 | -3.4% | -9.4% | +3.1% | |
| Q1 2019 | -0.8% | -1.0% | -10.7% | |
| Q4 2018 | +6.1% | +7.6% | -7.3% | |
| Q3 2018 | -12.3% | -15.3% | +4.4% | |
| Q2 2018 | +10.7% | +16.4% | +25.7% | |
| Q1 2018 | -6.9% | -9.7% | +11.5% | |
| Q4 2017 | -7.9% | -11.7% | -10.5% | |
| Q3 2017 | +3.2% | +12.0% | +66.5% | |
| Q2 2017 | -7.7% | -12.8% | +18.4% | |
| Q1 2017 | +2.6% | +7.9% | -2.2% | |
| Q4 2016 | -2.0% | -4.4% | -14.8% | |
| Q3 2016 | +15.3% | +18.2% | +5.2% | |
| Q2 2016 | +5.7% | +13.5% | +26.9% | |
| Q1 2016 | -2.7% | — | — | |
| Q4 2015 | -3.1% | — | — | |
| Q3 2015 | +11.1% | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro